The discovery and optimization of benzimidazoles as selective NaV1.8 blockers for the treatment of pain

被引：15

作者：

Brown, Alan D. ^{[1
]}

Bagal, Sharan K. ^{[1
]}

Blackwell, Paul ^{[2
]}

Blakemore, David C. ^{[4
]}

Brown, Bruce ^{[2
]}

Bungay, Peter J. ^{[3
]}

Corless, Martin ^{[2
]}

Crawforth, James ^{[2
]}

Fengas, David ^{[5
]}

Fenwick, David R. ^{[2
]}

Gray, Victoria ^{[2
]}

Kemp, Mark ^{[2
]}

Klute, Wolfgang ^{[2
]}

Sanz, Laia Malet ^{[2
]}

Miller, Duncan ^{[2
]}

Murata, Yoshihisa ^{[2
]}

Payne, C. Elizabeth ^{[3
]}

Skerratt, Sarah ^{[1
]}

Stevens, Edward B. ^{[3
]}

Warmus, Joseph S. ^{[4
]}

机构：

[1] Pfizer Ltd, Pfizer Med Design, Portway Bldg,Granta Pk, Cambridge CB21 6GS, England

[2] Pfizer Global R&D, Pfizer Med Sci, Sandwich CT13 9FF, Kent, England

[3] Pfizer Ltd, Med Sci, Portway Bldg,Granta Pk, Cambridge CB21 6GS, England

[4] Groton Labs, Pfizer Med Design, Eastern Point Rd, Groton, CT 06340 USA

[5] Concept Life Sci, Discovery Pk,Ramsgate Rd, Sandwich CT13 9FF, Kent, England

来源：

BIOORGANIC & MEDICINAL CHEMISTRY | 2019年 / 27卷 / 01期

关键词：

Benzimidazole; PF-06305591; Neuropathic pain; Inflammatory pain; Voltage gated sodium channel; Na(V)1.8; SCN10A; INHIBITORS; MUTATIONS; POTENT;

D O I：

10.1016/j.bmc.2018.12.002

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

The voltage gated sodium channel Na(V)1.8 has been postulated to play a key role in the transmission of pain signals. Core hopping from our previously reported phenylimidazole leads has allowed the identification of a novel series of benzimidazole Na(V)1.8 blockers. Subsequent optimization allowed the identification of compound 9, PF-06305591, as a potent, highly selective blocker with an excellent preclinical in vitro ADME and safety profile.

引用

页码：230 / 239

页数：10

共 50 条

[1] Discovery and Optimization of Selective Nav1.8 Modulator Series That Demonstrate Efficacy in Preclinical Models of Pain
Bagal, Sharan K.
Bungay, Peter J.
Denton, Stephen M.
Gibson, Karl R.
Glossop, Melanie S.
Hay, Tanya L.
Kemp, Mark I.
Lane, Charlotte A. L.
Lewis, Mark L.
Maw, Graham N.
Million, William A.
Payne, C. Elizabeth
Poinsard, Cedric
Rawson, David J.
Stammen, Blanda L.
Stevens, Edward B.
Thompson, Lisa R.
ACS MEDICINAL CHEMISTRY LETTERS, 2015, 6 (06): : 650 - 654
[2] Discovery and pharmacological evaluation of potent, selective blockers of the Nav1.8 sodium channel with efficacy in models of neuropathic pain
Kort, Michael E.
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2009, 237
[3] THE DISCOVERY OF HIGHLY SELECTIVE NaV1.8 MODULATORS WITH GOOD PHARMACOKINETIC PROPERTIES FOR CHRONIC MIXED PAIN
Kemp, Mark
DRUGS OF THE FUTURE, 2009, 34 : 16 - 17
[4] Nav1.8 channel blockade as an approach to the treatment of neuropathic pain
Weiser, Thomas
DRUGS OF THE FUTURE, 2006, 31 (07) : 597 - 601
[5] Selective Inhibition of NaV1.8 with VX-548 for Acute Pain
Jones, Jim
Correll, Darin J.
Lechner, Sandra M.
Jazic, Ina
Miao, Xiaopeng
Shaw, David
Simard, Christopher
Osteen, Jeremiah D.
Hare, Brian
Beaton, Alina
Bertoch, Todd
Buvanendran, Asokumar
Habib, Ashraf S.
Pizzi, Lois J.
Pollak, Richard A.
Weiner, Scott G.
Bozic, Carmen
Negulescu, Paul
White, Paul F.
NEW ENGLAND JOURNAL OF MEDICINE, 2023, 389 (05): : 393 - 405
[6] Nav1.7 and Nav1.8: Role in the pathophysiology of pain
Hameed, Shaila
MOLECULAR PAIN, 2019, 15
[7] Discovery and biological evaluation of potent, selective, orally bioavailable, pyrazine-based blockers of the Nav1.8 sodium channel with efficacy in a model of neuropathic pain
Scanio, Marc J. C.
Shi, Lei
Drizin, Irene
Gregg, Robert J.
Atkinson, Robert N.
Thomas, James B.
Johnson, Matthew S.
Chapman, Mark L.
Liu, Dong
Krambis, Michael J.
Liu, Yi
Shieh, Char-Chang
Zhang, XuFeng
Simler, Gricelda H.
Joshi, Shailen
Honore, Prisca
Marsh, Kennan C.
Knox, Alison
Werness, Stephen
Antonio, Brett
Krafte, Douglas S.
Jarvis, Michael F.
Faltynek, Connie R.
Marron, Brian E.
Kort, Michael E.
BIOORGANIC & MEDICINAL CHEMISTRY, 2010, 18 (22) : 7816 - 7825
[8] Discovery and biological evaluation of 5-aryl-2-furfuramides, potent and selective blockers of the Nav1.8 sodium channel with efficacy in models of neuropathic and inflammatory pain
Kort, Michael E.
Drizin, Irene
Gregg, Robert J.
Scanio, Marc J. C.
Shi, Lei
Gross, Michael F.
Atkinson, Robert N.
Johnson, Matthew S.
Pacofsky, Gregory J.
Thomas, James B.
Carroll, William A.
Krambis, Michael J.
Liu, Dong
Shieh, Char-Chang
Zhang, XuFeng
Hernandez, Gricelda
Mikusa, Joseph P.
Zhong, Chengmin
Joshi, Shailen
Honore, Prisca
Roeloffs, Rosemarie
Marsh, Kennan C.
Murray, Bernard P.
Liu, Jinrong
Werness, Stephen
Faltynek, Connie R.
Krafte, Douglas S.
Jarvis, Michael F.
Chapman, Mark L.
Marron, Brian E.
JOURNAL OF MEDICINAL CHEMISTRY, 2008, 51 (03) : 407 - 416
[9] Pharmacology and Mechanism of Action of Suzetrigine, a Potent and Selective NaV1.8 Pain Signal Inhibitor for the Treatment of Moderate to Severe Pain
Osteen, Jeremiah D.
Immani, Swapna
Tapley, Tim L.
Indersmitten, Tim
Hurst, Nicole W.
Healey, Tiffany
Aertgeerts, Kathleen
Negulescu, Paul A.
Lechner, Sandra M.
PAIN AND THERAPY, 2025, 14 (02) : 655 - 674
[10] Discovery of a novel series of pyridone amides as NaV1.8 inhibitors
Wang, Yanfang
Hu, Shilong
Chen, Yuhao
Chen, Meiyuan
Zhang, Di
Liu, Wencheng
Chen, Chunxia
Gan, Yu
Luo, Menglan
Ke, Bowen
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2024, 101

← 1 2 3 4 5 →